Studies have used doses ranging from 100 million to 10 billion CFU daily, with beneficial effects observed across this range
The most common side effects tend to involve digestion, since the medication slows how quickly food moves through the stomach
Our review expands upon this foundational work by incorporating post-2020 findings, emphasizing the bidirectional communication between taste bud cells (TBC) and gut endocrine signaling, and critically analyzing the potential clinical implications of GLP-1RAs on taste perception, food reward, and adherence to obesity treatment
(See Emerging evidence and recent advances.) The surprising positive outcomes of GLP-1 therapy observed in many disease processes are attributed to the drugs mechanism of action, secondary benefits of controlled disease processes, or disease prevention
While semaglutide and other GLP-1 medications are effective for some, not all women are candidates or may prefer alternative approaches